CN107137587A - A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof - Google Patents
A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof Download PDFInfo
- Publication number
- CN107137587A CN107137587A CN201710361418.9A CN201710361418A CN107137587A CN 107137587 A CN107137587 A CN 107137587A CN 201710361418 A CN201710361418 A CN 201710361418A CN 107137587 A CN107137587 A CN 107137587A
- Authority
- CN
- China
- Prior art keywords
- parts
- kidney
- animal
- reinforcing drug
- fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to tcm field, specifically a kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof, the kidney-reinforcing drug is using animal kidney as raw medicinal material or main ingredient material, and described animal kidney is tire kidney.Preparation method comprises the following steps：1) animal kidney is removed after connective tissue, smashed to pieces；2) cell separation is carried out in the animal kidney after smashing to pieces；3) kidney-derived cells isolated are subjected to broken wall using cell wall breaking technology；4) by step 3) kidney-derived cells are fabricated to oral formulations after broken wall.Present invention is generally directed to traditional Chinese medical science kidney deficiency, the kidney-reinforcing drug can play irreplaceable effect to senile osteoporosis, low reproductive function, premature ovarian failure and anti-aging.
Description
Technical field
The present invention relates to tcm field, a kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof is specifically related to.
Background technology
The present situation sharply increased in face of China's elderly population, how improving life of elderly person quality, preventing and treating disease of old people is mesh
Preceding China big problem to be solved.Basic Theories of Chinese Medicine is pointed out：Kidney be located at waist, backbone both sides, left and right each one, its is main
Function is store essential substances, main growth in humans, development and reproduction.There is raw, long, strong, old change with the prosperity and decline of kidney essense gas in all one's life of people
Change process.The gerontal patient of kidney deficiency, emphasis shows as integrating primary osteoporosis, premature ovarian failure, climacteric
These situations such as levy.
It is not that curative effect is not obvious although existing many kidney-reinforcing drugs, is exactly that conditioning effect is not comprehensive.Even if in life
Have and mend dirty dietary measure with dirty, but it has little effect mostly.
The content of the invention
In order to solve the above problems, the purpose of the present invention is：A kind of kidney-reinforcing drug of utilization animal kidney and its preparation side
Method, mainly for traditional Chinese medical science kidney deficiency, the kidney-reinforcing drug to senile osteoporosis, reproductive function low, premature ovarian failure and can prolong
Irreplaceable effect is played in slow aging.Special animal kidney uses tire kidney, and the kidney-reinforcing drug that it is prepared is evident in efficacy.
The technical scheme is that：A kind of kidney-reinforcing drug of utilization animal kidney, it is characterized in that：The kidney-reinforcing drug is with animal
Kidney is raw medicinal material or main ingredient material.
Described animal kidney is tire kidney.
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：30-50 parts of animal kidney, fruit of Chinese magnoliavine 10-20
Part, 5-20 parts of American Ginseng, 10-20 parts of the dried rhizome of rehmannia, 10-20 parts of saline cistanche, 5-15 parts of pilose antler, 5-15 parts of hippocampus, 10-20 parts of Radix Angelicae Sinensis,
10-15 parts of rhodiola root, 10-25 parts of cornus officinalis sieb et zucc, 6-12 parts of Chinese yam, 6-10 parts of radix polygonati officinalis, 6-10 parts of raspberry, 5-6 parts of the fruit of Chinese wolfberry,
5-9 parts of English walnut, 2-3 parts of the fruit of Cherokee rose.
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：45 parts of tire kidney, 15 parts of the fruit of Chinese magnoliavine, American Ginseng
10 parts, 15 parts of the dried rhizome of rehmannia, 15 parts of saline cistanche, 10 parts of pilose antler, 10 parts of hippocampus, 15 parts of Radix Angelicae Sinensis, 12 parts of rhodiola root, 20 parts of cornus officinalis sieb et zucc, mountain
10 parts of medicine, 8 parts of radix polygonati officinalis, 8 parts of raspberry, 5.5 parts of the fruit of Chinese wolfberry, 7 parts of English walnut, 1.5 parts of the fruit of Cherokee rose.
A kind of preparation method of the kidney-reinforcing drug of described utilization animal kidney, it is characterized in that：Comprise the following steps：
1) animal kidney is removed after connective tissue, smashed to pieces；
2) cell separation is carried out in the animal kidney after smashing to pieces；
3) kidney-derived cells isolated are subjected to broken wall using cell wall breaking technology；
4) by step 3) kidney-derived cells are fabricated to oral formulations after broken wall.
A kind of preparation method of the kidney-reinforcing drug of described utilization animal kidney, it is characterized in that：Comprise the following steps：
Step 1) by after 30-50 parts of removal connective tissues of animal kidney, smash to pieces；
Step 2) cell separation is carried out in animal kidney after smashing to pieces；
Step 3) use cell wall breaking technology to carry out broken wall the kidney-derived cells isolated；It is standby；
Step 4) by 10-20 parts of the fruit of Chinese magnoliavine, 5-20 parts of American Ginseng, 10-20 parts of the dried rhizome of rehmannia, 10-20 parts of saline cistanche, pilose antler 5-
15 parts, 5-15 parts of hippocampus, 10-20 parts of Radix Angelicae Sinensis, 10-15 parts of rhodiola root, 10-25 parts of cornus officinalis sieb et zucc, 6-12 parts of Chinese yam, radix polygonati officinalis 6-10
Part, 6-10 parts of raspberry, 5-6 parts of the fruit of Chinese wolfberry, 5-9 parts of English walnut, the 2-3 parts of gross weights by above-mentioned parts by weight of the fruit of Cherokee rose add 4-
The decocting of 5 times of amounts is boiled 2 hours, takes slag to add the decocting of 3 times of amounts to boil again 1.5 hours, is filtered by several times, and merging filtrate is heated to 50-
70 DEG C are concentrated into relative density 1.10-1.30 thick pastes；
Step 5) when step 4) thick paste temperature at 40 DEG C, add step 3) the kidney-derived cells stirring after broken wall is equal
It is even；
Step 6) by step 5) mixture is fabricated to oral formulations.
Described oral formulations are suspension or capsule；Wherein, the content containing kidney-derived cells is 20-150 millis in suspension
Grams per milliliter.
Described cell separation is to carry out cell separation using nanometer technology.
The process that described nanometer technology carries out cell separation is：The first step prepares Nano-meter SiO_22Coating particles, Nano-meter SiO_22
Nano-meter SiO_2 of the Particle size control after 15~20nm, cladding2The size of coating particles is 30nm；Second step be prepare containing
The polyvinylpyrrolidone colloidal solution of kidney-derived cells：Rear animal kidney and polyvinylpyrrolidone in mass ratio 1 will be smashed to pieces：2
It is mixed to form colloidal solution；3rd step is by Nano-meter SiO_22Coating particles evenly spread to the polyethylene pyrrole containing kidney-derived cells
In pyrrolidone colloidal solution, then by centrifugation technique, using density gradient principle, separate kidney-derived cells.
It is an advantage of the invention that：The kidney-reinforcing drug of the present invention can be used in preventing and treating primary bone because caused by increasing age kidney deficiency
The diseases such as matter is loose, premature ovarian failure, menopausal syndrome, it easily absorbs, and effect is notable.The Chinese medicinal material of auxiliary is equipped with simultaneously
Make its effect more fully.The protein ingredient containing bioactivity can be improved in the tire kidney that the present invention is used, its kidney-derived cells
Blood calcium, Calcitonin Level, reduce urine HOP and parathyroid gland cellulose content；Osteoporosis is had some improvement.This hair
Clear-cells separation is to carry out cell separation using nanometer technology easily to form density gradient；Particularly nanometer cladding size exists
30nm, thus colloidal solution is easy to generation density gradient under the action of the centrifugal, and easily realize Nano-meter SiO_22Particle and cell
Separation.Because Nano-meter SiO_22Particulate be belong to unorganic glass category performance it is stable, typically not with colloidal solution and life
Thing solution reaction, will not both stain biological cell, also easily separate them.The present invention additionally uses breaking-wall cell skill simultaneously
Art, the medicine of the invention made easily absorption of human body.
The present invention is described in further details below by specific embodiment, but it is not as a limitation of the invention.
Embodiment
Embodiment 1
A kind of kidney-reinforcing drug of utilization animal kidney is using animal kidney as raw medicinal material；
This is comprised the following steps using the preparation method of the kidney-reinforcing drug of animal kidney：
1) animal kidney is removed after connective tissue, smashed to pieces；
2) cell separation is carried out in the animal kidney after smashing to pieces；
3) kidney-derived cells isolated are subjected to broken wall using cell wall breaking technology；
4) by step 3) kidney-derived cells are fabricated to oral formulations after broken wall.
Embodiment 2
A kind of kidney-reinforcing drug of utilization animal kidney is using animal kidney as raw medicinal material；
This is comprised the following steps using the preparation method of the kidney-reinforcing drug of animal kidney：
1) animal kidney is removed after connective tissue, smashed to pieces；
2) cell separation is carried out in the animal kidney after smashing to pieces；Described cell separation is carried out using nanometer technology
Cell separation；
3) kidney-derived cells isolated are subjected to broken wall using cell wall breaking technology；
4) by step 3) kidney-derived cells are fabricated to oral formulations after broken wall.
Above-mentioned nanometer technology carries out cell separation and uses prior art here using cell wall breaking technology progress broken wall
Do not do and state one by one.
Described oral formulations are suspension or capsule；Wherein, the content containing kidney-derived cells is 20-150 millis in suspension
Grams per milliliter.
Embodiment 3
Be the same as Example 2 is essentially identical, except that the process that described nanometer technology carries out cell separation is：First
Step prepares Nano-meter SiO_22Coating particles, Nano-meter SiO_22Nano-meter SiO_2 of the Particle size control after 15~20nm, cladding2Coat grain
The size of son is 30nm；Second step is to prepare the polyvinylpyrrolidone colloidal solution containing kidney-derived cells：Rear animal will be smashed to pieces
Kidney and polyvinylpyrrolidone in mass ratio 1：2 are mixed to form colloidal solution；3rd step is by Nano-meter SiO_22Coating particles
Evenly spread in the polyvinylpyrrolidone colloidal solution containing kidney-derived cells, then by centrifugation technique, utilize density gradient
Principle, separates kidney-derived cells.
The animal kidney is young age dog kidney or young age sheep kidney.
Embodiment 4
A kind of kidney-reinforcing drug of utilization animal kidney is made up of following raw materials by following weight parts：30 parts of animal kidney, five
10 parts of taste, 5 parts of American Ginseng, 10 parts of the dried rhizome of rehmannia, 10 parts of saline cistanche, 5 parts of pilose antler, 5 parts of hippocampus, 10 parts of Radix Angelicae Sinensis, 10 parts of rhodiola root,
10 parts of cornus officinalis sieb et zucc, 6 parts of Chinese yam, 6 parts of radix polygonati officinalis, 6 parts of raspberry, 5 parts of the fruit of Chinese wolfberry, 5 parts of English walnut, 2 parts of the fruit of Cherokee rose；
A kind of preparation method of the kidney-reinforcing drug of described utilization animal kidney, comprises the following steps：
Step 1) by after 30 parts of removal connective tissues of animal kidney, smash to pieces；
Step 2) cell separation is carried out in animal kidney after smashing to pieces；
Step 3) use cell wall breaking technology to carry out broken wall the kidney-derived cells isolated；It is standby；
Step 4) by 10 parts of the fruit of Chinese magnoliavine, 5 parts of American Ginseng, 10 parts of the dried rhizome of rehmannia, 10 parts of saline cistanche, 5 parts of pilose antler, 5 parts of hippocampus, when
Return 10 parts, 10 parts of rhodiola root, 10 parts of cornus officinalis sieb et zucc, 6 parts of Chinese yam, 6 parts of radix polygonati officinalis, 6 parts of raspberry, 5 parts of the fruit of Chinese wolfberry, 5 parts of English walnut, gold
2 parts of gross weights by above-mentioned parts by weight of cherry add the 4-5 times of decocting measured to boil 2 hours, take slag to add the decocting of 3 times of amounts to boil again
1.5 hours, filter by several times, merging filtrate is heated to 50-70 DEG C and is concentrated into relative density 1.10-1.30 thick pastes；
Step 5) when step 4) thick paste temperature at 40 DEG C, add step 3) the kidney-derived cells stirring after broken wall is equal
It is even；
Step 6) by step 5) mixture is fabricated to oral formulations.
Embodiment 5
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：50 parts of animal kidney, 20 parts of the fruit of Chinese magnoliavine, west
20 parts of American ginseng, 20 parts of the dried rhizome of rehmannia, 20 parts of saline cistanche, 15 parts of pilose antler, 15 parts of hippocampus, 20 parts of Radix Angelicae Sinensis, 15 parts of rhodiola root, cornus officinalis sieb et zucc 25
Part, 12 parts of Chinese yam, 10 parts of radix polygonati officinalis, 10 parts of raspberry, 6 parts of the fruit of Chinese wolfberry, 9 parts of English walnut, 3 parts of the fruit of Cherokee rose.
Preparation method be the same as Example 4.Cell separation is to carry out cell separation using nanometer technology, the nanometer technology and is adopted
Broken wall is carried out with cell wall breaking technology not do state one by one here using prior art.Described oral formulations are suspension
Or capsule.
Embodiment 6
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：45 parts of animal kidney, 15 parts of the fruit of Chinese magnoliavine, west
10 parts of American ginseng, 15 parts of the dried rhizome of rehmannia, 15 parts of saline cistanche, 10 parts of pilose antler, 10 parts of hippocampus, 15 parts of Radix Angelicae Sinensis, 12 parts of rhodiola root, cornus officinalis sieb et zucc 20
Part, 10 parts of Chinese yam, 8 parts of radix polygonati officinalis, 8 parts of raspberry, 5.5 parts of the fruit of Chinese wolfberry, 7 parts of English walnut, 1.5 parts of the fruit of Cherokee rose.
Preparation method be the same as Example 5.The process that described nanometer technology carries out cell separation is：The first step prepares nanometer
SiO2Coating particles, Nano-meter SiO_22Nano-meter SiO_2 of the Particle size control after 15~20nm, cladding2The size of coating particles is
30nm；Second step is to prepare the polyvinylpyrrolidone colloidal solution containing kidney-derived cells：Rear animal kidney and poly- second will be smashed to pieces
Alkene pyrrolidone in mass ratio 1：2 are mixed to form colloidal solution；3rd step is by Nano-meter SiO_22Coating particles are evenly spread to
In polyvinylpyrrolidone colloidal solution containing kidney-derived cells, then by centrifugation technique, using density gradient principle, make kidney
Source cell is separated.
Use cell wall breaking technology progress broken wall not do here for prior art to state one by one.The animal kidney is children
Age dog tire kidney or young age sheep placenta kidney.
Described oral formulations are suspension or capsule.
Embodiment 7
A kind of kidney-reinforcing drug of utilization animal kidney is made up of following raw materials by following weight parts：30 parts of tire kidney, the fruit of Chinese magnoliavine
10 parts, 5 parts of American Ginseng, 10 parts of the dried rhizome of rehmannia, 10 parts of saline cistanche, 5 parts of pilose antler, 5 parts of hippocampus, 10 parts of Radix Angelicae Sinensis, 10 parts of rhodiola root, sweet potato
10 parts of meat, 6 parts of Chinese yam, 6 parts of radix polygonati officinalis, 6 parts of raspberry, 5 parts of the fruit of Chinese wolfberry, 5 parts of English walnut, 2 parts of the fruit of Cherokee rose；
A kind of preparation method of the kidney-reinforcing drug of described utilization animal kidney, comprises the following steps：
Step 1) by after 30 parts of removal connective tissues of tire kidney, smash to pieces；
Step 2) cell separation is carried out in tire kidney after smashing to pieces；
Step 3) use cell wall breaking technology to carry out broken wall the kidney-derived cells isolated；It is standby；
Step 4) by 10 parts of the fruit of Chinese magnoliavine, 5 parts of American Ginseng, 10 parts of the dried rhizome of rehmannia, 10 parts of saline cistanche, 5 parts of pilose antler, 5 parts of hippocampus, when
Return 10 parts, 10 parts of rhodiola root, 10 parts of cornus officinalis sieb et zucc, 6 parts of Chinese yam, 6 parts of radix polygonati officinalis, 6 parts of raspberry, 5 parts of the fruit of Chinese wolfberry, 5 parts of English walnut, gold
2 parts of gross weights by above-mentioned parts by weight of cherry add the 4-5 times of decocting measured to boil 2 hours, take slag to add the decocting of 3 times of amounts to boil again
1.5 hours, filter by several times, merging filtrate is heated to 50-70 DEG C and is concentrated into relative density 1.10-1.30 thick pastes；
Step 5) when step 4) thick paste temperature at 40 DEG C, add step 3) the kidney-derived cells stirring after broken wall is equal
It is even；
Step 6) by step 5) mixture is fabricated to oral formulations.
Embodiment 8
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：50 parts of tire kidney, 20 parts of the fruit of Chinese magnoliavine, American Ginseng
20 parts, 20 parts of the dried rhizome of rehmannia, 20 parts of saline cistanche, 15 parts of pilose antler, 15 parts of hippocampus, 20 parts of Radix Angelicae Sinensis, 15 parts of rhodiola root, 25 parts of cornus officinalis sieb et zucc, mountain
12 parts of medicine, 10 parts of radix polygonati officinalis, 10 parts of raspberry, 6 parts of the fruit of Chinese wolfberry, 9 parts of English walnut, 3 parts of the fruit of Cherokee rose.
Preparation method be the same as Example 7.Cell separation is to carry out cell separation using nanometer technology, the nanometer technology and is adopted
Broken wall is carried out with cell wall breaking technology not do state one by one here using prior art.Described oral formulations are suspension
Or capsule.
Embodiment 9
Described kidney-reinforcing drug is made up of following raw materials by following weight parts：45 parts of tire kidney, 15 parts of the fruit of Chinese magnoliavine, American Ginseng
10 parts, 15 parts of the dried rhizome of rehmannia, 15 parts of saline cistanche, 10 parts of pilose antler, 10 parts of hippocampus, 15 parts of Radix Angelicae Sinensis, 12 parts of rhodiola root, 20 parts of cornus officinalis sieb et zucc, mountain
10 parts of medicine, 8 parts of radix polygonati officinalis, 8 parts of raspberry, 5.5 parts of the fruit of Chinese wolfberry, 7 parts of English walnut, 1.5 parts of the fruit of Cherokee rose.
Preparation method be the same as Example 7.The process that described nanometer technology carries out cell separation is：The first step prepares nanometer
SiO2Coating particles, Nano-meter SiO_22Nano-meter SiO_2 of the Particle size control after 15~20nm, cladding2The size of coating particles is
30nm；Second step is to prepare the polyvinylpyrrolidone colloidal solution containing kidney-derived cells：Rear tire kidney and polyethylene pyrrole will be smashed to pieces
Pyrrolidone in mass ratio 1：2 are mixed to form colloidal solution；3rd step is by Nano-meter SiO_22Coating particles evenly spread to containing
In the polyvinylpyrrolidone colloidal solution of kidney-derived cells, then by centrifugation technique, using density gradient principle, make kidney source thin
Born of the same parents separate.
Use cell wall breaking technology progress broken wall not do here for prior art to state one by one.The animal kidney is dog
Tire kidney or sheep placenta kidney.
Described oral formulations are suspension or capsule.
Pharmacological research
1. influence of the tire kidney to old rats sex hormone and bone density
Using 20 monthly age SD female senile rats as experimental animal, 40 rats are randomly divided into experimental group and control group, given
Experimental group injects the tire mouse kidney cell suspension of pregnant 19-21 days from tail vein, 2 times a week, totally 2 weeks, control group injection equivalent life
Salt solution is managed, rat is put to death within 1 month, 2 months in batches after injection respectively, specimen taken exempts from method detection serum estradiol with putting
(E2) content, ovary is weighed, and osteopathy reason Morphological measurement and Appearance View are carried out with multi-functional true color pathological image analysis system
Examine.Its result is shown：Compared Foetus renal cells group estrogen level (table 1.1) with control group and ovarian index (table 1.2) is significantly carried
Height, ovarian atrophy degree substantially mitigates；Obvious broadening, the bone trabecula spacing of bone trabecula width substantially diminishes, bone trabecula surface density
Significantly rise, cortex thickness of bone are obvious broadening (table 1.3).Prompting：Foetus renal cells are for delaying ovarian-senescence, improving aged bone
Matter is loose obvious effect.
Kidney controlling essence storage, main growth in humans, development and reproduction, estrogen level, ovarian index can reflect reproductive function,
Bone density is the mark of bone strength, and it is the arrogant performance declined of kidney essense that it, which changes, and improvement prompting of the Foetus renal cells to it can with kidney
Kidney tonifying.
Serum estradiol level is compareed after the cell transplantation of table 1.1
* P ＜ 0.01
Ovarian index is compareed after the cell transplantation of table 1.2
* P ＜ 0.01
Bones morphology measurement control after the cell transplantation of table 1.3
* P ＜ 0.001**P ＜ 0.01***P ＞ 0.05****P ＜ 0.05
2. influence of the tire kidney to osteoporosis model rat calcium-regulating hormone
It is experimental animal from 3-4 monthly ages SD female rats to inquire into the mechanism of action that tire kidney prevents and treats osteoporosis,
24 rats are randomly divided into 3 groups, i.e. Normal group, model group, Foetus renal cells group, in addition to Normal group, remaining 2 groups
Modeling is carried out using vitamin A acid.After modeling, hanged to the tire mouse kidney cell that Foetus renal cells group is injected pregnant 19-21 days from tail vein
Liquid, 2 times a week, Normal group, model group input normal saline the 30th day, all animals are placed in metabolic cage,
Twenty-four-hour urine liquid is collected, eye socket blood sampling, sacrificed by decapitation takes left tibias.Estradiol (E2), calcitonin are determined using method of exempting from is put
(CT), parathormone (PTH), BGP (BGP) content, osteopathy is carried out with multi-functional true color pathological image analysis system
Manage Morphological measurement and morphologic observation.Its result is shown：Compared with Normal group, model group E2, CT, BGP level substantially drops
It is low, the significantly raised (P of PTH<0.05)；Compared with model group, Foetus renal cells group CT, E2, BGP significantly increase, serum PTH is obvious
Decline (P<0.05) (table 2.1).Compared with Normal group, model group bone trabecula area, thickness are substantially reduced, between bone trabecula
Away from increase (P<0.05)；Compared with model group, Foetus renal cells group bone trabecula area, thickness, dramatically increased, bone trabecula spacing
Reduce (P<0.05) (table 2.2).Its result is pointed out：Tire kidney can effectively improve osteoporosis, its cure mechanism with rise blood calcium,
Calcitonin content, improves E2 levels；Reduce parathormone relevant.Illustrate that tire kidney can effectively suppress the bone information of osteoclast；
Promote calcium in the deposition of bone, be conducive to the mineralising of bone；Reduce the decomposition of collagen.
The measurement result of each group rat portions calcium-regulating hormone of table 2.1
Note：Compared with Normal group*P ＜ 0.05, " P ＜ 0.01；Compared with model groupΔP ＜ 0.05,P ＜ 0.01；n
=8
The each group rat cancellous bone norphometry result of table 2.2
Note：Compared * P ＜ 0.05, " P ＜ 0.01 with Normal group；Compared with model groupΔP ＜ 0.05,P ＜ 0.01；n
=8
3. tire kidney prevents and treats the active principle research of osteoporosis
In order to inquire into the active principle that tire kidney prevents and treats osteoporosis, seminar to SD female ovariectomized rats by causing
Osteoporosis model, model control group (B groups) is randomly divided into by modeling rat, and estrogen positive control group (C groups), tire kidney is lived
Groups of cells (D groups) and tire kidney dead cell group (E groups), and set Sham-operated control group (A groups).Experimental group is given from tail vein note respectively
Tire kidney living cells and dead cell suspension are penetrated, estrogen positive control group gives Nilestriol gavage, sham-operation group and model control group
Tail vein injection normal saline, 2 times a week, totally 4 weeks.After medication terminates, bone specimen is left and taken in fasting 24 hours, blood sampling,
Its influence to modeling rat bone pathomorphism, dry weight, ash weight, skeleton metabolism and estrogen level is observed, tire kidney is inquired into
The active principle of osteoporosis is prevented and treated, its result is shown：Foetus renal cells each group substantially changes osteoporosis in ovariectomized rats
Pathomorphism, makes density, the thickness increase of its bone trabecula, and the gap shrinks of bone trabecula are joined to bone trabecula morphometry static state
Number index is significantly improved effect；Ovariectomized Rats backbone weight, bone ash weight and bone length is set to have raised,
Shin bone physical quantity indexes are had some improvement.Foetus renal cells each group significantly improves ovariectomized female rats blood serum E2, BGP
Level is raised, and makes the reduction of serum N TX contents；Significantly raise serum calcium, phosphorus level；Increase bone calcium, bone phosphorus content.It is acted on
There was no significant difference with estrogen positive control group.
Compare between Foetus renal cells each group, tire kidney dead cell group improve ovariectomized female rats serum paraoxonase, calcium, E2, BGP level,
Increase its trabecular bone density, reduce bone trabecula gap, the key weight of increase, bone ash weight, bone length and bone matrix content and reduction blood
The effect of clear NTX levels is superior to tire kidney living cells group, but both no significant differences (P ＞ 0.05)；Tire kidney living cells
Increase of the group to trabeculae in ovariectomized rats area percentage, bone calcium and bone phosphorus content, better than tire kidney dead cell group, and both
Difference is also not statistically significant (P ＞ 0.05).Illustrate that tire kidney prevents and treats the active principle and Foetus renal cells work, dead property of osteoporosis
Relation less, may be relevant with certain protein ingredient therein.
Clinical test
The clinical test of the kidney-reinforcing drug of utilization animal kidney of the present invention is as follows：
Table 3：The kidney-reinforcing drug of 4- of embodiment of the present invention embodiments 9 is respectively adopted, 40-50 Sui patient of age is 50, year
Equal 50 of 60-70 Sui patient of age, each 25 of every group of men and women (is referred to as treatment group 1-6) successively.Course of disease March-August, average course of disease
5.5 months.Patient did not receive other treatment before kidney-reinforcing drug of the present invention is taken.Ten are a course for the treatment of, and 20 days laggard
Row symptom score.
Using Guilubushen Tablet：Chinese medicines quasi-word Z20080217,40-50 Sui patient of age 50,60-70 Sui patient of age
50, each 25 of every group of men and women (referred to as compares A groups).Course of disease March-August, average course of disease 5.5 months.Patient is taking the medicine
It is preceding all not receive other treatment.Ten are a course for the treatment of, and symptom score is carried out after 20 days.
Using Liuwei Dihuang Wan, 40-50 Sui patient of age 50,60-70 Sui patient of age 50, every group of men and women each 25
Name (referred to as compares B groups).Course of disease March-August, average course of disease 5.5 months.Patient did not receive other before the medicine is taken
Treatment.Ten are a course for the treatment of, and symptom score is carried out after 20 days.
The symptom of above-mentioned patient is：Senile osteoporosis or premature ovarian failure.
Mark of the senile osteoporosis using bone density as bone strength judges that premature ovarian failure is with estrogen level
Or ovarian index judges.
Observe result：
Take after 20 days, effect is relatively shown in Table 3.
The kidney-reinforcing drug of the present invention of table 3 is taken effect after 20 days and compared
From table 3, using efficient the having apparently higher than control A groups and control B groups of the made kidney-reinforcing drug of the present invention
Efficiency, the side effect number of cases of made kidney-reinforcing drug of the invention is then 1, hence it is evident that less than control A groups and control B groups, as a result show this
Invent made kidney-reinforcing drug evident in efficacy.Particularly the present invention uses tire kidney more notable for the kidney-reinforcing drug effect of main ingredient.
The present invention is when without Chinese herbs medicinal material, and method of administration is easy, sufficient with medicine source, has no side effect safely
The characteristics of, while adding some Chinese herbs medicinal materials again, its curative effect is more notable, has broad application prospects.
Embodiment does not have detailed narrating process step to belong to the well-known components and conventional means of the industry, does not chat one by one here
State.
Claims (9)
1. a kind of kidney-reinforcing drug of utilization animal kidney, it is characterized in that：The kidney-reinforcing drug is using animal kidney as raw medicinal material or main ingredient material.
2. a kind of kidney-reinforcing drug of utilization animal kidney according to claim 1, it is characterized in that：Described animal kidney is tire
Kidney.
3. a kind of kidney-reinforcing drug of utilization animal kidney according to claim 1 or 2, it is characterized in that：Described kidney-reinforcing drug is
It is made up of following raw materials by following weight parts：30-50 parts of animal kidney, 10-20 parts of the fruit of Chinese magnoliavine, 5-20 parts of American Ginseng, dried rhizome of rehmannia 10-
20 parts, 10-20 parts of saline cistanche, 5-15 parts of pilose antler, 5-15 parts of hippocampus, 10-20 parts of Radix Angelicae Sinensis, 10-15 parts of rhodiola root, cornus officinalis sieb et zucc 10-
25 parts, 6-12 parts of Chinese yam, 6-10 parts of radix polygonati officinalis, 6-10 parts of raspberry, 5-6 parts of the fruit of Chinese wolfberry, 5-9 parts of English walnut, 2-3 parts of the fruit of Cherokee rose.
4. a kind of kidney-reinforcing drug of utilization animal kidney according to claim 3, it is characterized in that：Described kidney-reinforcing drug is under
Raw material is stated to constitute by following weight parts：45 parts of tire kidney, 15 parts of the fruit of Chinese magnoliavine, 10 parts of American Ginseng, 15 parts of the dried rhizome of rehmannia, 15 parts of saline cistanche, deer
Fine and soft 10 parts, 10 parts of hippocampus, 15 parts of Radix Angelicae Sinensis, 12 parts of rhodiola root, 20 parts of cornus officinalis sieb et zucc, 10 parts of Chinese yam, 8 parts of radix polygonati officinalis, 8 parts of raspberry, Chinese holly
5.5 parts of matrimony vine, 7 parts of English walnut, 1.5 parts of the fruit of Cherokee rose.
5. a kind of preparation method of the kidney-reinforcing drug of utilization animal kidney according to claim 1 or 2, it is characterized in that：Including
Following steps：
1) animal kidney is removed after connective tissue, smashed to pieces；
2) cell separation is carried out in the animal kidney after smashing to pieces；
3) kidney-derived cells isolated are subjected to broken wall using cell wall breaking technology；
4) by step 3) kidney-derived cells are fabricated to oral formulations after broken wall.
6. a kind of preparation method of the kidney-reinforcing drug of utilization animal kidney according to claim 3, it is characterized in that：Including as follows
Step：
Step 1) by after 30-50 parts of removal connective tissues of animal kidney, smash to pieces；
Step 2) cell separation is carried out in animal kidney after smashing to pieces；
Step 3) use cell wall breaking technology to carry out broken wall the kidney-derived cells isolated；It is standby；
Step 4) by 10-20 parts of the fruit of Chinese magnoliavine, 5-20 parts of American Ginseng, 10-20 parts of the dried rhizome of rehmannia, 10-20 parts of saline cistanche, 5-15 parts of pilose antler,
5-15 parts of hippocampus, 10-20 parts of Radix Angelicae Sinensis, 10-15 parts of rhodiola root, 10-25 parts of cornus officinalis sieb et zucc, 6-12 parts of Chinese yam, 6-10 parts of radix polygonati officinalis, cover basin
Sub- 6-10 parts, 5-6 parts of the fruit of Chinese wolfberry, 5-9 parts of English walnut, the 2-3 parts of gross weights by above-mentioned parts by weight of the fruit of Cherokee rose add the 4-5 times of water measured
Decoct 2 hours, take slag to add the decocting of 3 times of amounts to boil again 1.5 hours, filter by several times, merging filtrate is heated to 50-70 DEG C and is concentrated into
Relative density 1.10-1.30 thick pastes；
Step 5) when step 4) thick paste temperature at 40 DEG C, add step 3) kidney-derived cells after broken wall stir；
Step 6) by step 5) mixture is fabricated to oral formulations.
7. a kind of preparation method of the kidney-reinforcing drug of utilization animal kidney according to claim 5 or 6, it is characterized in that：It is described
Oral formulations be suspension or capsule；Wherein, the content containing kidney-derived cells is 20-150 mg/mls in suspension.
8. a kind of preparation method of the kidney-reinforcing drug of utilization animal kidney according to claim 5 or 6, it is characterized in that：It is described
Cell separation be using nanometer technology carry out cell separation.
9. a kind of preparation method of the kidney-reinforcing drug of utilization animal kidney according to claim 8, it is characterized in that：Described receives
Rice technology carry out cell separation process be：The first step prepares Nano-meter SiO_22Coating particles, Nano-meter SiO_22Particle size control is 15
Nano-meter SiO_2 after~20nm, cladding2The size of coating particles is 30nm；Second step is to prepare the polyethylene containing kidney-derived cells
Pyrrolidones colloidal solution：Rear animal kidney and polyvinylpyrrolidone in mass ratio 1 will be smashed to pieces：2 are mixed to form colloidal solution；
3rd step is by Nano-meter SiO_22Coating particles are evenly spread in the polyvinylpyrrolidone colloidal solution containing kidney-derived cells, then
By centrifugation technique, using density gradient principle, separate kidney-derived cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710361418.9A CN107137587A (en) | 2017-05-22 | 2017-05-22 | A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710361418.9A CN107137587A (en) | 2017-05-22 | 2017-05-22 | A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107137587A true CN107137587A (en) | 2017-09-08 |
Family
ID=59777258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710361418.9A Pending CN107137587A (en) | 2017-05-22 | 2017-05-22 | A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137587A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112107600A (en) * | 2020-10-26 | 2020-12-22 | 张哲� | Nanometer medicinal preparation for treating pigmentation, and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1256921A (en) * | 1998-12-17 | 2000-06-21 | 西安医科大学第一临床医学院 | Anti-senility medicine for preventing and treating senile osteoporosis |
| CN101584797A (en) * | 2008-05-22 | 2009-11-25 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome |
| CN101940718A (en) * | 2010-10-08 | 2011-01-12 | 王欢 | Kidney-tonifying health care medicated wine |
| CN101940702A (en) * | 2010-08-11 | 2011-01-12 | 内蒙古永业生物技术有限责任公司 | Health-care medicated wine and preparation method thereof |
-
2017
- 2017-05-22 CN CN201710361418.9A patent/CN107137587A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1256921A (en) * | 1998-12-17 | 2000-06-21 | 西安医科大学第一临床医学院 | Anti-senility medicine for preventing and treating senile osteoporosis |
| CN101584797A (en) * | 2008-05-22 | 2009-11-25 | 河北以岭医药研究院有限公司 | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome |
| CN101940702A (en) * | 2010-08-11 | 2011-01-12 | 内蒙古永业生物技术有限责任公司 | Health-care medicated wine and preparation method thereof |
| CN101940718A (en) * | 2010-10-08 | 2011-01-12 | 王欢 | Kidney-tonifying health care medicated wine |
Non-Patent Citations (5)
| Title |
|---|
| 彭宁，等: "胎肾细胞悬液对维甲酸所致骨质疏松大鼠部分钙调节激素的影响", 《中国骨质疏松杂志》 * |
| 郑清莲，等，: "胎肾细胞移植预防和改善骨质疏松的动物实验研究", 《陕西中医》 * |
| 陶杰，等: "《生物制药工艺技术》", 28 February 2013, 中国医药科技出版社 * |
| 高学敏，等: "《临床中药学》", 31 January 2006, 河北科学技术出版社 * |
| 高焕民，等: "《纳米医学》", 31 May 2006, 军事医学科学出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112107600A (en) * | 2020-10-26 | 2020-12-22 | 张哲� | Nanometer medicinal preparation for treating pigmentation, and its preparation method |
| CN112107600B (en) * | 2020-10-26 | 2024-04-05 | 张哲� | Nanometer medicinal preparation for treating pigmentation diseases, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103110744B (en) | Traditional Chinese medical health-care preparation for increasing bone density and preparation method thereof | |
| CN104873624A (en) | Pharmaceutical composition for treating gouty arthritis | |
| CN109276710A (en) | A kind of composition and its preparation method and application increasing bone density | |
| CN109453188B (en) | Application of sandworm polysaccharide in preparation of medicine for preventing and treating osteoporosis | |
| CN113713067B (en) | Traditional Chinese medicine composition for preventing and treating sarcopenia osteoporosis and preparation method thereof | |
| CN1706463A (en) | Medicine for treating women's habitual abortion and threatened abortion | |
| CN113116897B (en) | Application of magnoflorine in preparation of bone-regulating drug synergist and drug composition containing magnoflorine | |
| CN107137587A (en) | A kind of kidney-reinforcing drug of utilization animal kidney and preparation method thereof | |
| CN107073060A (en) | Chinese cassia tree and the water extract of the Radix Astragali | |
| CN110812445B (en) | Pharmaceutical composition for preventing and/or treating osteoporosis and preparation method and application thereof | |
| CN1939383B (en) | Use of redback christmashush in preparing medicine for hepatitis B | |
| CN100542548C (en) | A kind of Chinese medicine preparation for the treatment of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN109276598B (en) | Enriched glossy privet fruit glycoside and application thereof | |
| CN109700918A (en) | Traditional Chinese medicine composition for treating postmenopausal osteoporosis | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN108465031A (en) | A kind of Chinese medicine composition and preparation method thereof for treating osteoporosis | |
| CN102526195A (en) | Medicinal composition for treating coronary disease and preparation method thereof | |
| CN107510838A (en) | A kind of cell preparation and its preparation method and application | |
| KR100486968B1 (en) | Composition of health care beverage containing silkworm extract | |
| CN105687924A (en) | Traditional Chinese medicine composition for harmonizing stomach and setting fracture and preparation method thereof | |
| CN101632723B (en) | Application of compound polygonum orientale preparation in preventing and treating climacteric diseases and delaying senility | |
| CN116440182A (en) | Traditional Chinese medicine composition for promoting height growth and preparation method and application thereof | |
| CN105497127A (en) | Nerve protection use of Chinese medicinal composition | |
| CN109793846A (en) | A kind of Chinese medicine composition | |
| CN117618396A (en) | Naomaili granule, preparation method thereof and application of Naomaili granule in neuroprotection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zheng Qinglian Inventor after: Da Chenxing Inventor after: Sun Yujiao Inventor after: Yu Chen Inventor after: Bian Zhuoqiong Inventor after: Liu Die Inventor after: Cai Yun Inventor after: Zhang Zhe Inventor after: Liu Juntian Inventor after: Li Xinmin Inventor after: Liu Yonghui Inventor after: Zhao Xin Inventor after: Peng Ning Inventor after: Peng Yu Inventor after: Shen Yan Inventor before: Zheng Qinglian Inventor before: Da Chenxing Inventor before: Sun Yujiao Inventor before: Yu Chen Inventor before: Bian Zhuoqiong Inventor before: Liu Die Inventor before: Cai Yun Inventor before: Liu Juntian Inventor before: Li Xinmin Inventor before: Liu Yonghui Inventor before: Zhang Zhe Inventor before: Zhao Xin Inventor before: Peng Ning Inventor before: Peng Yu Inventor before: Shen Yan |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170908 |